

Part of the
Tech Center 1600
JUL 26 2001

RECEIVED

In Re Application of: REVEL et al
Application No.: 09/462,416
Filed: April 13, 2000
For: CHIMERIC INTERLEUKIN-6 SOLUBLE RECEPTOR/LIGAND PROTEIN, ...

THE UNITED STATES PATENT AND TRADEMARK OFFICE



Art Unit: 1646
Examiner: N. Basi
Washington, D.C.
Atty.'s Docket: REVEL=15
Date: July 24, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a [] Amendment [XX] Response to Notice to Comply; with Sequence Listing and Disk in the above-identified application.

- [] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.
 No additional fee is required.
 The fee has been calculated as shown below:

	(Col. 1)	(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	MINUS ** 20	0
INDEP.	*	MINUS *** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM			

ADDITIONAL FEE TOTAL \$

SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
x 9	\$		x 18	\$
x 40	\$		x 80	\$
+ 135	\$		+ 270	\$
		OR		
			TOTAL	\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

- Conditional Petition for Extension of Time
 If any extension of time for a response is required, applicant requests that this be considered a petition therefor.
- [] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- [] First - \$ 55.00
 [] Second - \$ 195.00
 [] Third - \$ 445.00
 [] Fourth - \$ 695.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

- [] First - \$ 110.00
 [] Second - \$ 390.00
 [] Third - \$ 890.00
 [] Fourth - \$ 1390.00

Month After Time Period Set


[] Less fees (\$ _____) already paid for _____ month(s) extension of time on _____.


- [] Please charge my Deposit Account No. 02-4035 in the amount of \$ _____.
 [] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ _____.
 [] A check in the amount of \$ _____ is attached (check no. _____).

- The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By: 
 Allen C. Yun
 Registration No. 37,971



Application No.: 09/462 416

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



#91C
RECEIVED
4128101 JUL 26 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit: 1646
REVEL et al)
Appln. No.: 09/462,416) Examiner: N. Basi
Filed: April 13, 2000) Washington, D.C.
For: CHIMERIC INTERLEUKIN-6) July 24, 2001
SOLUBLE RECEPTOR/LIGAND)
PROTEIN, ANALOGS THEREOF)
AND USES THEREOF) Atty.Docket: REVEL=15

**RESPONSE TO NOTICE TO COMPLY WITH
SEQUENCE LISTING REQUIREMENTS**

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply dated June 29, 2001, and prior to the examination of the above-described application, please amend the present application as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at line 7 of page 8 with the following rewritten paragraph:

--(vi) A chimeric sIL-6R/IL-6 protein, being the herein designated sIL-6R δ Val/L/IL-6 having a 13 amino acid peptide linker of sequence E-F-G-A-G-L-V-L-G-G-Q-F-M (SEQ ID NO:1) between the C-terminal Val-356 of sIL-6R and the N-terminal Pro-29 of IL-6R, said chimeric protein having the sequence set forth in Fig. 3 wherein the tripeptide of sequence E-F-M between positions 357-359 of Fig. 3 is replaced by said 13 amino acid peptide sequence.--